AzTrials
AzTrials

CataractNCT05639049

Performance of Two Hydrophobic IOLs

A study testing Enova GF3 and Tecnis 1-piece ZCB00 in people with Cataract, run by Vienna Institute for Research in Ocular Surgery at 1 site in Austria.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Comparison of the capsular bag performance of two hydrophobic intraocular lenses of different design. Read more about this study

Who is it for?
Ages 21 to 105 years
Conditions the study is for
Cataract
What is being tested?
Enova GF3 and Tecnis 1-piece ZCB00
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteAustria
Study dates
1 Nov 2022to 1 Nov 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 105 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age-related bilateral cataract
  • Age 21 or older
  • Visual acuity > 0.05
  • Normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant
  • Written informed consent prior to surgery

Who cannot join

  • Relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), traumatic cataract, intraoperative Floppy Iris Syndrome (IFIS), or other co-morbidities that could affect capsular bag stability (e.g. Marfan syndrome)
  • Any ophthalmic comorbidity that may compromise visual function or create problems with measurements (e.g. macular degeneration, amblyopia, corneal scars, etc.)
  • Previous ocular surgery or trauma
  • Pregnancy (pregnancy test will be taken in women of reproductive age)

Trial locations and contacts

1 site in 1 country.

Christoph Spartalis, MD contact

01 91021 ext. 57564

office@viros.at

Manuel Ruiss, MSc contact

01 91021 ext. 57564

office@viros.at

Austria1 site, 1 recruiting
  • Vienna Institute for Research in Ocular Surgery (VIROS), Hanusch Hospital Vienna

    Vienna, 1140

    Oliver Findl, MD, MBA, +43 91021 ext. 57564, office@viros.at

    Recruiting

Other trials in Austria

About this study

Official title: Capsular Bag Performance of Two Hydrophobic Intraocular Lenses of Different Design

Comparison of the capsular bag performance of two hydrophobic intraocular lenses of different design.

Read the detailed description

Continuous improvements in cataract surgery technique, intraocular lens (IOL) materials, and design over the past few decades, have led to a more safe procedure with satisfactory refractive outcomes and a short rehabilitation time. By that, patients' expectations concerning their postoperative visual quality and refractive outcome are increasing. However, two main problems might occur after cataract surgery: instability of the IOL position in the capsular bag and formation of posterior capsule opacification (PCO). Both may decrease the optical performance of an IOL.

The performance of an IOL depends on its behaviour in the capsular bag, which has an influence on the anterior chamber depth (ACD), as well as the postoperative refractive shift, the tilt and decentration of the IOL. Several factors such as IOL design and material, capsulorhexis size, capsular bag diameter, and capsular fibrosis or shrinkage may lead to a suboptimal IOL position. Misalignment of an IOL away from the retina leads to a myopic shift, while towards the retina leads to a hyperopic outcome. This explains why inaccurate prediction of postoperative ACD remains the main source of error in IOL power calculation.

One main goal of modern cataract surgery is to yield a low and predictable ACD shift as well as low degrees of IOL tilt and decentration after surgery in order to achieve ideal optical performance of the IOL.

Another aspect of capsular bag performance of an IOL is posterior capsule opacification (PCO). PCO is one of the most frequent long-term complications after cataract surgery leading to dissatisfying results by decreased visual function. Source of PCO are lens epithelial cells from the equator of the lens capsule, which acquire the ability to migrate and proliferate, causing epithelial ingrowth between the IOL and the posterior capsule. It is estimated that PCO occurs at a rate of 12% one year, 21% three years, and 28% five years after cataract surgery. PCO can be treated with neodymium-doped yttrium aluminium garnet (Nd:YAG) laser capsulotomy. However, complications including an increase in intraocular pressure, ocular inflammation, cystoid macular edema, and retinal detachment may occur after this treatment. Hence lower rates of PCO would improve patients long term safety following cataract surgery. Moreover, it would increase patient satisfaction.

The material and design of an IOL may have an effect on the formation of PCO. Sharp optic edge design has been shown to be a major factor in the prevention of PCO. Furthermore, acrylic and silicone hydrophobic materials showed a lower risk for PCO formation and lower rates of postoperative Nd:YAG laser capsulotomy than hydrophilic IOLs.

In this study the ACD shift and IOL tilt and centration as well as the PCO formation of an IOL with a new design, the Enova GF3 IOL will be compared to a standard monofocal IOL, the Tecnis 1-piece ZCB00.

90 eyes of 45 patients will be included into this study. According to the randomization, the ENOVA GF3 will be implanted in one eye and the ZCB00 in the fellow eye of each patient. Follow-up visits will take place 1 week, 3 months, 6 months, and 12 months after the surgery. At each visit a slitlamp examination, non-contact intraocular pressure measurement, refraction, visual acuity testing, biometry, retroillumination photography, and purkinjemeter assessments will be performed.

Conditions
Cataract
Being tested
Enova GF3, Tecnis 1-piece ZCB00
Keywords
Cataract, Cataract surgery
Medical subject headings
Cataract

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Enova GF3Device

    Enova GF3, monofocal IOL

  • Tecnis 1-piece ZCB00Device

    Tecnis 1-piece ZCB00, monofocal IOL

Study groups in NCT05639049
Study groupRoleWhat they receive
Enova GF3ExperimentalPatient will receive the monofocal IOL in one eye during cataract surgery
Receives: Device: Enova GF3
Tecnis 1-piece ZCB00ExperimentalPatient will receive the monofocal IOL in one eye during cataract surgery
Receives: Device: Tecnis 1-piece ZCB00

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Anterior chamber depth

    Anterior chamber depth will be assessed using a biometry device and will be compared between both monofocal IOLs

    Measured: 24 months

Secondary outcomes (4)
  1. IOL tilt

    IOL tilt will be assessed using the purkinjemeter and will be compared between both IOLs

    Measured: 24 months

  2. Posterior capsule opacification (PCO)

    PCO will be assessed using retroillumination photography and will be compared between both groups

    Measured: 24 months

  3. Visual acuity

    Visual acuity will be assessed in the far and intermediate distance using ETDRS charts and will be compared between both groups

    Measured: 24 months

  4. Catquest 9SF questionnaire

    The Catquest 9SF questionnaire will be handed out to all patients

    Measured: 24 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted6 Dec 2022
  2. Study start1 Nov 2022
  3. Primary completion1 Nov 2023 (estimated)
  4. Study completion1 Nov 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
45 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05639049
Sponsor's protocol ID
Enova
Status last verified
Nov 2022
First submitted
28 Nov 2022
Last updated
6 Dec 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Enova GF3 and Tecnis 1-piece ZCB00 in people with Cataract, run by Vienna Institute for Research in Ocular Surgery at 1 site in Austria.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 6 Dec 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Christoph Spartalis, MD (01 91021 ext. 57564, office@viros.at), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Anterior chamber depth (time frame: 24 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Dec 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in